

관상동맥내 CrossFlex 스텐트 삽입술 후 초기성적 : 다기관 연구결과

CrossFlex 스텐트 연구그룹

Immediate Results After CrossFlex Stent Implantation

CrossFlex Stent Study Group

Multicenter Trial

ABSTRACT

Background : The CrossFlex™ stent is a flexible, balloon-expandable new device with an excellent flexibility, radial strength, and conformability. The aim of this study was to evaluate the safety and efficacy of the new CrossFlex stent in the treatment of native coronary artery diseases. **Methods** : The CrossFlex™ stent was implanted in 328 consecutive patients (mean age 60 ± 10 , M/F=2.6 : 1) with the 345 lesions. Stent deployment was accomplished with a single inflation to 14-16 atmospheres without adjunct high-pressure balloon dilatation (single high pressure technique). Intravascular ultrasound (IVUS) imaging was performed to evaluate the results of stent deployment in selected patients. **Results** : The indications for stent implantation were elective in 304 lesions (88.1%), suboptimal angioplasty results in 15 lesions (4.4%), and threatened or acute vessel closure in 26 lesions (7.5%). Procedural success rate was 99.1%, and nonfatal myocardial infarction occurred in 3 patients (0.9%) after stent deployment. The minimal lumen diameter increased from 0.8 ± 0.4 to 3.2 ± 0.5 mm, and the diameter stenosis decreased from 74 ± 13 to $0.5 \pm 9\%$. IVUS was performed in 40 lesions at the time of stent implantation. The IVUS images after stenting seemed to be more like slotted-tube stents than coil stents. Mild plaque prolapse within the stent occurred in 3 lesions. There were no lesions of incomplete stent apposition using single high-pressure technique. **Conclusions** : The CrossFlex™ stent is a safe and effective device with a high procedural success rate for treatment of native coronary artery disease. Further studies may be needed to assess late clinical outcomes of this stent. (Korean Circulation J 1998;28(10):1685-1690)

KEY WORDS : CrossFlex stent · Coronary artery disease · Clinical outcome.

서 론

1-3) CrossFlex™ Ta-
2
2
Tantalum Cordis

(balloon expandable)

3) Tantalum Cor -

: 1998 8 17

: 1998 10 20

: , 138 - 040

388 - 1

dis

: (02) 224 - 3150 ·

: (02) 475 - 6898

Tantalum Cordis

가 가 , 5,000 가

가 가 , 가 2

가 CrossFlex™ Tantalum Cordis

(radial 혈관내 초음파 촬영
force) (stainless) Intravascular ultrasound(IVUS)
CrossFlex™

0.2 mg
14 (ultrasound catheter) 10 mm
, 0.5 mm/sec
(motorized automatic pullback de-
vice)

대상 및 방법

연구대상 IVUS Cardiovas-
cular Imaging System 30-
1996 4 1997 12 14 MHz (transducer)가 , 360 °
328 345 382 가 [2.9 F (imaging she-
ath) , 3.2 F] 가
CrossFlex 가 1) Thallium
SPECT 가 , 2) VHS
(quantitative coronary angiograp-
hic analysis, QCA) 50% 항혈전 요법
, 3) 가 aspirin ticlopidine
, aspirin ticlopidine , ticlopidine 1
250 mg 1
, aspirin 200 mg

스텐트 삽입술

conventional balloon 혈관조영 분석

가 1 : 1 (percent
diameter stenosis) (minimal luminal diam-
eter) ANCOR V2.0, Siemens
14~16 (quantitative coronary angiography)
single high pressure technique , 가
(30%)
가 .
30% , recoil
(,) (acute stent recoil) :
10,000 acute stent recoil (%) = (mean balloon diameter - final
activated clotting time 250 mean lumen diameter)/mean balloon diameter × 100

정량적 IVUS 분석
(vessel lumen) exte -
rnal elastic membrane , (cr -
oss sectional area)
(reference vessel)
10 mm 가

41 (11.9%) 2
, 97 (28.2%) 2

시술결과

Table 2 Table 3

통계 분석

±
paired t test

결 과

환자 및 병소의 특성

328 Table 1
. 99.1% , 341
304(88.1%)
, 15(4.4%)
, 26(7.5%)
8.1% 35% . AHA/
ACC B2 C 가 47% ,

Table 1. Clinical characteristics of the 328 patients

Charateristics	
Age (years)	60.2 ± 9.8
Sex (male/female)	236/92
Risk factors	
Hypertension	146 (44.5%)
Diabetes mellitus	81 (24.7%)
Hypercholesterolemia (> 240 mg/dl)	42 (12.8%)
Current smoker	161 (49.1%)
Family history	16 (4.9%)
Unstable angina	153 (46.6%)
Recent myocardial infarction (< 2 weeks)	93 (28.4%)
LVEF	57.4 ± 10.9
Diseased vessels, n	
1	137(41.8%)
2	120(36.6%)
3	71(21.6%)

LVEF : left ventricular ejection fraction

Table 2. Angiographic characteristics of the 345 lesions

Characteristics	
Artery dilated	
LAD	163 (46.8%)
LCX	77 (22%)
RCA	105 (30%)
Lesion morphology	
A	19 (5.5%)
B1	163 (47.2%)
B2	107 (31%)
C	55 (15.9%)
Indications	
Elective	304 (88.1%)
Suboptimal	15 (4.4%)
Bailout	26 (7.5%)
De Novo lesion	335 (97%)
Restenotic lesion	10 (3%)
Proximal reference vessel diameter (mm)	3.25 ± 0.43
Balloon to artery ratio	1.11 ± 0.26
Maximal balloon inflation pressure (atm)	13.8 ± 3.0
Minimal lumen diameter (mm)	
Baseline	0.83 ± 0.43
Final	3.23 ± 0.39
Percent diamter stenosis (%)	
Baseline	74.1 ± 13.4
Final	0.5 ± 9.2
Acute gain (mm)	2.43 ± 0.53
Acute recoil (%)	5.0 ± 3.6

LAD : left anterior descending coronary artery

LCX : left circumflex coronary artery

RCA : right coronary artery

Table 3. Clinical outcomes after CrossFlex stent implantation

Procedural success	325(99.1%)
Clinical events	
Death	0(0%)
Nonfatal myocardial infarction	3(0.9%)
Subacute stent thrombosis	0(0%)

99.1% , 3
 Q
 3.25 ± 0.43 mm,
 1.11 ± 0.26 . 75
 $\pm 14\%$ $0.7 \pm 9.4\%$ ($p < 0.05$).
 0.8 ± 0.4 mm 3.2 ± 0.4
 mm 가 ($p < 0.05$) 2.4 ± 0.5 mm
 recoil $5 \pm 4\%$,
 Palmaz - Schatz stent Tantalum Cordis stent
 (radiopacity) Fig. 1
 (2 mm)
 8.5%

IVUS 분석
 IVUS 40
 IVUS
 (apposition) (expansion)
 (Fig. 2).
 (tissue prolapse) 3(7.5%)
 가 ,
 (apposition)

Table 3. Clinical outcomes after CrossFlex stent implantation

Procedural success	325(99.1%)
Clinical events	
Death	0(0%)
Nonfatal myocardial infarction	3(0.9%)
Subacute stent thrombosis	0(0%)




Fig. 2. Intravascular ultrasound images after stent implantation.



Fig. 1. Comparison of radiopacity : The radiopacity of CrossFlex stent (left) shows an ideal balance between Palmaz-Schatz stent (right) and Tantalum Cordis stent (middle). Arrows indicate stents before injection of contrast dye.

고 안

CrossFlex™

가 10 mm, 15 mm, 25 mm

CrossFlex™

CrossFlex™

가

CrossFlex™

profile

가

(standard stent)

가

(apposition) (ex -

pansion)

가

요 약

6.6%

recoil 5%

(radial force)

(slotted

연구배경 :

tube)

⁵⁾

CrossFlex™

CrossFlex

2

single high pressure tec -

Tantalum Cordis

hnique

CrossFlex™

CrossFlex™

CrossFlex

(elective stenting)

(bailout procedure)

방 법 :

Tantalum Cordis

1996 4

1997 12

328

345

382

CrossFlex

(strong radiopacity)

가

1)

Cross -

Thallium SPECT

Flex™

Tantalum Cordis

가

2)

³⁾⁴⁾

Tantalum Cordis

50%

3)

가

Tantalum Cordis

1416

가

IVUS

⁴⁾

CrossFlex™

(apposition)

(expansion)

recoil Palmaz - Schatz

⁶⁻⁹⁾

, Palmaz - Schatz

결 과 :

99.1%

, 3

profile

가

가

3.25 ± 0.43 mm,

1.1

CrossFlex™

가 1

1 ± 0.26

75 ± 14%

가

0.7 ± 9.4%

0.8

CrossFlex™

15 mm

± 0.4 mm

3.2 ± 0.4 mm

가

2.4 ± 0.5 mm . recoil 5%
 . IVUS
 (apposition) (expansion)
 . 7.5% mild
 tissue prolapse가 (appos -
 ition)

결 론 :

CrossFlex™

감사문

Cordis a Johnson & Johnson Corp.

가 Johnson & Johnson Corp.

Cordis a

CrossFlex 스텐트 연구위원회 구성

Coordinating center :

Study centers, collaborated investigators :

가

가

Principal investigator,

REFERENCES

- 1) Almagor Y, Feld S, Leon MB, et al. First international new intravascular rigid-flex endovascular stent study (FIT-NESS): Clinical and angiographic results after elective and urgent stent implantation. *J Am Coll Cardiol* 1997; 30:847-54.
- 2) Carrozza JP, Hermiller JB, Baim DS, et al. Quantitative coronary angiographic and intravascular ultrasound assessment of a new nonarticulated stent: Report form the advanced cardiovascular systems Multilink stent pilot study. *J Am Coll Cardiol* 1998;31:50-6.
- 3) Park SJ, Park SW, Hong MK, et al. Late clinical outcomes of Cordis tantalum coronary stenting without anticoagulation. *Am J Cardiol* 1997;80:943-7.
- 4) Park SW, Park SJ, Hong MK, et al. Coronary stenting (Cordis) without anticoagulation. *Am J Cardiol* 1997;79:901-4.
- 5) Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. *Circulation* 1995;91:1676-88.
- 6) Painter JA, Mintz GS, Wong SC, et al. Serial intravascular ultrasound studies fail to show evidence of chronic Palmaz-Schatz stent recoil. *Am J Cardiol* 1997;75:398-400.
- 7) Fishman DL, Leon MB, Baim D, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. *N Engl J Med* 1994;331:496-501.
- 8) Serruys PW, de Jaegere P, Kiemeneij F, et al. For the Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. *N Eng J Med* 1994;331:489-95.
- 9) Laham R, Carrozza JP, Berger C, Cohen DJ, Kuntz RE, Baim DS. Long-term (4-to 6-year) outcome of Palmaz-Schatz stenting: Paucity of late clinical stent-related problems. *J Am Coll Cardiol* 1996;28:820-6.